GUTS - NASDAQ

Fractyl Health, Inc. Common Stock

GUTS·NASDAQ

$0.76

-3.1%

HealthcareBiotechnology

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$54.87M

EPS-1.8600

P/E Ratio-0.41

Earnings Date08/11/2026

121.40M

Assets

12%

3Y+99.0%

5Y+249.0%

10Y+1259.0%

111.94M

Total Liabilities

41%

3Y-64.0%

5Y+465.0%

10Y-27.0%

9.46M

Total Equity

-67%

3Y-104.0%

5Y-37.0%

10Y-107.0%

Fractyl Health, Inc. Common Stock Funding & Solvency Profile

GUTS · NASDAQ

Current Assets

Cash & Cash Equivalents81.54M

Net Receivables0.00

Inventory0.00

Other Current Assets6.04M

Total Current Assets88 M

Non-Current Assets

Property, Plant & Equipment29.23M

Goodwill & Intangible Assets0.00

Long-Term Investments4.25M

Other Non-Current Assets337.00K

Total Non-Current Assets34 M

Total Assets

121.40M

Financial Health Analysis

Current Ratio

4.78x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

11.84x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

69 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

72% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Fractyl Health, Inc. Common Stock Balance Sheet

GUTS • NASDAQ

Fractyl Health, Inc. Common Stock Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	81.5M	67.5M	33.5M	49.3M	95.5M	29.1M	5.8M
Cash & Short-Term Investments	81.5M	67.5M	33.5M	49.3M	95.5M	29.1M	5.8M
Net Receivables	0.0	0.0	22K	0.0	0.0	0.0	0.0
Accounts Receivables	0.0	0.0	22K	0.0	0.0	0.0	0.0
Inventory	0.0	73K	73K	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	0.0	1.8M	986K
Other Current Assets	6M	4.2M	2M	2.4M	915K	0.0	0.0
Total Current Assets	87.6M	71.8M	35.6M	51.6M	96.4M	30.9M	6.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	29.2M	31.4M	30.8M	1.6M	1.3M	1.4M	2.1M
Intangible Assets	0.0	0.0	835K	863K	0.0	0.0	0.0
Goodwill & Intangible Assets	0.0	0.0	835K	863K	0.0	0.0	0.0
Long-Term Investments	4.3M	4.3M	4.3M	4.3M	0.0	0.0	0.0
Other Non-Current Assets	337K	666K	4.7M	2.6M	4.8M	2.5M	32K
Total Non-Current Assets	33.8M	36.3M	40.6M	9.3M	6.2M	3.9M	2.2M
Total Assets	121.4M	108.1M	76.2M	61M	102.5M	34.8M	8.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.6M	3.2M	553K	980K	970K	304K	608K
Accounts Payable	1.6M	3.2M	553K	980K	970K	304K	608K
Accrued Expenses	5.7M	4.2M	3.5M	2.8M	1.9M	2.8M	860K
Short Term Debt	5.1M	0.0	2.7M	0.0	15.7M	7.2M	0.0
Capital Lease Obligations (Current)	0.0	5M	0.0	1.3M	950K	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	-980K	-970K	0.0	0.0
Other Current Liabilities	6M	7.4M	4.4M	3.3M	5.1M	672K	1.9M
Total Current Liabilities	18.3M	19.8M	11.2M	7.3M	23.7M	10.9M	3.4M
NON-CURRENT LIABILITIES
Long Term Debt	30.6M	30.2M	342.5M	305.1M	287.3M	8.1M	14.9M
Other Non-Current Liabilities	37.1M	2.3M	19.1M	409K	555K	769K	134.6M
Total Non-Current Liabilities	93.6M	59.9M	390.1M	306M	288.2M	8.9M	149.5M
Capital Lease Obligations	26M	32.3M	28.5M	1.7M	1.3M	0.0	0.0
Total Liabilities	111.9M	79.7M	401.3M	313.3M	311.9M	19.8M	152.9M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	187.7M	133.1M
Common Stock	1K	0.0	0.0	0.0	0.0	0.0	20.7M
Additional Paid-In Capital	565.7M	443.7M	21.6M	17.2M	13.7M	11.6M	9.9M
Retained Earnings	-556.3M	-415.3M	-346.6M	-269.5M	-223.1M	-184.3M	-153.9M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	-153.9M
Total Stockholders' Equity	9.5M	28.4M	-325.1M	-252.3M	-209.3M	15M	-144M
Total Equity	9.5M	28.4M	-325.1M	-252.3M	-209.3M	15M	-144M
SUMMARY
Total Liabilities & Equity	121.4M	108.1M	76.2M	61M	102.5M	34.8M	8.9M
Total Investments	4.3M	4.3M	4.3M	4.3M	0.0	0.0	0.0
Total Debt	61.6M	62.5M	373.7M	306.8M	304.3M	15.3M	148M
Net Debt	-19.9M	-5M	340.2M	257.5M	208.9M	-13.8M	142.2M
Shares Outstanding	72,193,770	72,193,770	72,193,770	72,193,770	72,193,770	72,193,770	72,193,770

SEC Filings

GUTS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	April 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 24, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 17, 2026	March 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 29, 2026	January 29, 2026	2026	View Filing
8-K 8-K 2025 N/A	January 06, 2026	December 30, 2025	2025	View Filing

Showing 1 to 10 of 54 filings

Related Guides

Blog Categories

Continue your GUTS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.